Reviewing PharmaCyte Biotech (OTCMKTS:PMCBD) and Vaxcyte (NASDAQ:PCVX)

Vaxcyte (NASDAQ:PCVX) and PharmaCyte Biotech (OTCMKTS:PMCBD) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, earnings, profitability and risk.

Insider & Institutional Ownership

96.8% of Vaxcyte shares are held by institutional investors. Comparatively, 0.0% of PharmaCyte Biotech shares are held by institutional investors. 3.1% of Vaxcyte shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Volatility & Risk

Vaxcyte has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500. Comparatively, PharmaCyte Biotech has a beta of 0.27, indicating that its share price is 73% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and target prices for Vaxcyte and PharmaCyte Biotech, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxcyte	0	0	7	0	3.00
PharmaCyte Biotech	0	0	0	0	0.00

Vaxcyte currently has a consensus price target of $147.50, indicating a potential upside of 72.01%. Given Vaxcyte’s stronger consensus rating and higher probable upside, analysts clearly believe Vaxcyte is more favorable than PharmaCyte Biotech.

Profitability

This table compares Vaxcyte and PharmaCyte Biotech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vaxcyte	N/A	-23.53%	-22.20%
PharmaCyte Biotech	N/A	-49.09%	-43.39%

Valuation and Earnings

This table compares Vaxcyte and PharmaCyte Biotech”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxcyte	N/A	N/A	-$402.27 million	($4.60)	-18.64
PharmaCyte Biotech	N/A	N/A	-$3.83 million	N/A	N/A

Summary

Vaxcyte beats PharmaCyte Biotech on 8 of the 9 factors compared between the two stocks.

About Vaxcyte

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

About PharmaCyte Biotech

PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes. The company was founded on October 28, 1996 and is headquartered in Laguna Hills, CA.